How Tirzepatide and Retatrutide Compare for Women's Weight Loss

Your body changed faster than any product could keep up with, and now you're deep in the research phase, comparing peptides the way you used to compare foundation shades. Good. The data on these two compounds is genuinely exciting, and this breakdown gives you the numbers, the side effects, the real costs, and the decision framework to pick your route.

Retatrutide's first Phase 3 results show 28.7% body weight loss at 68 weeks versus tirzepatide's 22.5% at 72 weeks. That's a meaningful gap. But retatrutide isn't available by prescription yet and carries a higher adverse-event rate. For women evaluating next-gen GLP-1 peptides in 2025, tirzepatide is the one you can get prescribed today, while retatrutide is the stronger-on-paper option worth tracking for a late 2026 or 2027 approval. Here's how they actually stack up.

Key Takeaways

• Retatrutide (triple agonist) delivered 28.7% weight loss at 68 weeks in Phase 3 trials; tirzepatide (dual agonist) delivered 22.5% at 72 weeks, a roughly 6-percentage-point gap.
• 73.4% of retatrutide participants lost ≥20% of body weight versus 57% on tirzepatide, meaning your odds of hitting a major transformation are higher with the triple agonist.
• Tirzepatide is FDA-approved and available now via brand ($1,000–1,200/month, 2025 list) or compounded telehealth ($250–500/month). Retatrutide has no legal prescription pathway until at least late 2026.
• Both cause GI side effects concentrated in the first 4–8 weeks of dose escalation. Retatrutide's overall adverse-event rate is roughly 48% higher (RR 4.10 vs. 2.78 relative to placebo).
• A direct head-to-head trial (NCT06662383) is currently enrolling and will give us the first apples-to-apples comparison, likely reporting in 2027–2028.
• If you've never tried a GLP-1 peptide, [take the quiz](#quiz) to find your starting point based on your goals, timeline, and medical history.

---

Why Women Are Comparing These Two Peptides Right Now

Six months ago the conversation was semaglutide vs. tirzepatide. That's settled. Tirzepatide wins on weight loss, and most women who've done their homework already know that. The new question is whether the next compound, retatrutide, is worth waiting for or worth accessing early.

This isn't idle curiosity. Women over 35 lose muscle and metabolic flexibility faster than the trial populations studied in these drugs, and the difference between 22% and 29% total body weight loss can be the difference between looking "thinner" and looking completely different. Between needing a body lift and not. Between maintaining your results on a low dose and fighting regain.

The real decision point is dual agonist versus triple agonist. Tirzepatide activates two hormone receptors. Retatrutide activates three. That third receptor (glucagon) changes the metabolic math in ways that matter specifically for women dealing with stubborn visceral fat, fatty liver, and the insulin resistance that accelerates after perimenopause. So yes, you're right to be comparing them. Let's get into what the data actually shows.

---

What Tirzepatide and Retatrutide Actually Do Differently

Both are injectable peptides made by Eli Lilly. Both suppress appetite. Both improve insulin sensitivity. But they pull different levers.

Tirzepatide is a dual agonist: it activates GLP-1 receptors (the ones semaglutide hits, responsible for appetite suppression and slowed gastric emptying) and GIP receptors (glucose-dependent insulinotropic polypeptide, which enhances insulin secretion and appears to improve fat metabolism). Think of it as semaglutide's smarter, stronger sister. Two signals instead of one, working in concert to reduce hunger and improve how your body processes energy.

Retatrutide is a triple agonist: it hits those same two receptors plus the glucagon receptor. Glucagon is the hormone that tells your liver to release stored glucose and ramp up energy expenditure. Activating it does two things that matter for body composition:

1. Increased energy expenditure. Your body burns more calories at rest. This is the thermogenic effect women on retatrutide protocols notice as running slightly warmer.
2. Liver fat reduction. The Phase 2 trial published in the New England Journal of Medicine showed retatrutide reduced liver fat by over 80% in participants with metabolic dysfunction-associated steatotic liver disease. For women with elevated liver enzymes or diagnosed fatty liver (increasingly common in perimenopause and post-menopause), this is a big deal.

That third receptor is both the advantage and the wildcard. Glucagon agonism is why retatrutide produces more weight loss. It's also why the side-effect profile is slightly different and why the long-term safety data still needs to catch up. The mechanism is sound. The early data is strong. The question is just how the risk-benefit ratio plays out over years of use, and that's what the ongoing Phase 3 program (TRIUMPH) is answering.

---

Head-to-Head Weight Loss Data: 22.5% vs 28.7%

These aren't subtle differences. Here's what the two flagship trials showed:

A few things to notice. Retatrutide achieved more weight loss in less time (68 weeks vs. 72). The responder rates are striking: nearly three out of four women on retatrutide 12mg lost 20% or more of their body weight, compared to just over half on tirzepatide. And a network meta-analysis comparing the two compounds confirmed retatrutide's superiority on both absolute and percentage weight reduction.

Now, the caveats that actually matter. TRIUMPH-4's population was smaller (445 vs. 2,539) and specifically included people with knee osteoarthritis, which means a population that may be more motivated and more metabolically burdened. SURMOUNT-1 was a broader obesity trial. These aren't perfectly matched comparisons.

That's exactly why the ongoing head-to-head trial (NCT06662383) matters. It's directly comparing retatrutide and tirzepatide in the same population, and results will likely read out in 2027 or 2028. Until then, the indirect comparison favors retatrutide, but we're working with strong-but-imperfect evidence.

Evidence grade: Tirzepatide weight loss, strong human evidence (A-tier, multiple Phase 3 trials, thousands of participants). Retatrutide weight loss, strong early evidence (B-tier, Phase 2 published in NEJM, first Phase 3 results announced, full publication pending).

---

Side Effects Women Should Actually Prepare For

Let's be direct about what the first two months feel like on either of these, because that's when most women decide whether to push through or quit.

The GI reality for both compounds: Nausea, diarrhea, decreased appetite (which is partly the point), and occasional vomiting. These are GLP-1 class effects. They happen because these peptides slow gastric emptying (your stomach takes longer to move food through), and your body needs time to adjust.

• Nausea: up to 32%
• Diarrhea: 23%
• Vomiting: 12%
• Constipation: 11%

For retatrutide, the Phase 2 NEJM trial showed a similar GI profile with one important addition: dose-dependent heart rate increases that peaked at 24 weeks and then declined. This is likely the glucagon receptor at work (glucagon has mild chronotropic effects). The increases were modest and didn't lead to cardiovascular events in the trial, but your provider will want to monitor heart rate, especially if you have a history of tachycardia or are on stimulant medications.

The meta-analysis puts retatrutide's overall adverse-event relative risk at 4.10 versus tirzepatide's 2.78. That's roughly 48% higher. Most of that excess is GI, and most of it is concentrated during dose escalation. Starting retatrutide at 2mg (rather than 4mg) partially mitigated GI issues in the Phase 2 trial, which is why slow titration will almost certainly be the standard protocol.

What weeks 1–8 actually feel like, practically:

Weeks 1–2: Appetite drops noticeably. Some nausea, usually worst 24–48 hours after injection. Eating smaller portions feels natural, not forced.

Weeks 3–6: GI symptoms either stabilize or intensify depending on dose escalation. This is when women report the most discomfort. Eating high-fat or large meals becomes genuinely unpleasant. Many women find that bland, protein-forward, smaller meals are the path of least resistance.

Weeks 6–8: For most women, the body adjusts. Nausea becomes background noise rather than the main event. This is when the scale starts moving in ways that feel real.

Genuine medical contraindications to flag: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a hard stop for both compounds. History of pancreatitis warrants a serious conversation with your provider. Gallbladder disease risk increases with rapid weight loss on any GLP-1 agonist. If you're on insulin or sulfonylureas, doses need adjustment to avoid hypoglycemia. These are the things your provider will ask about and check before prescribing.

---

What Each One Costs and How to Get It Today

This is where the comparison gets real, because access is the deciding factor for most women right now.

Tirzepatide is FDA-approved and on the market under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It's also available as a compounded formulation through telehealth providers.

Retatrutide is not FDA-approved. Phase 3 trials (the TRIUMPH program) are ongoing, with the first positive results from TRIUMPH-4 announced in December 2025. Eli Lilly has not filed for FDA approval yet. The earliest realistic approval date is late 2026, more likely 2027.

For tirzepatide, the compounded route through telehealth is how most women without insurance coverage or with high copays are accessing it. Typical compounded tirzepatide runs $250–500/month in 2025, depending on dose and provider. The process: you complete an intake, a licensed clinician reviews your labs and history (expect them to want a recent A1C, metabolic panel, and your BMI), and the medication ships to your door. It's a weekly subcutaneous injection you do yourself. If you're new to injectable peptides, our guide on syringe units and dosing walks through the math that most providers skip.

Like most research peptides in the injectable space, retatrutide isn't FDA-approved for any indication yet, which is exactly why the interesting real-world evidence lives in what women are reporting and what the clinical trial data shows. Women on peptide-focused forums and communities who have accessed retatrutide as a research compound consistently report aggressive appetite suppression, noticeable body recomposition, and faster results than they experienced on tirzepatide or semaglutide. These are anecdotal reports, not controlled data, but the pattern is consistent with what the trials predict.

For retatrutide access, the conversation is with a peptide-literate clinic or provider who stays current on research compounds. Functional medicine doctors, anti-aging clinics, and telehealth platforms that specialize in peptide protocols are the places to ask. Our guide on which doctors prescribe peptides covers exactly how to find the right provider and what to say in that first appointment.

---

Who Should Start Tirzepatide Now vs Wait for Retatrutide

The honest framework comes down to three variables: how much you want to lose, how fast you want to start, and what your metabolic picture looks like.

Start tirzepatide now if:

• You want results you can see in 3–6 months, not 18–24 months from now. Time has a cost. Every month you spend "waiting for the better option" is a month you're not losing weight, not building the habits that maintain it, and not experiencing what it feels like to live in a different body.
• 20–22% body weight loss meets your goal. For a woman starting at 200 lbs, that's 40–45 lbs. For many women, that's the difference between feeling invisible and feeling like themselves again.
• You want a clear, legal, well-documented prescription pathway with established dosing protocols and a provider who's managed hundreds of patients on the same drug.
• You're new to GLP-1 peptides entirely. Tirzepatide is a better first compound because the safety data is deeper, the dosing is well-established, and you'll learn how your body responds to this class of drug before considering anything more aggressive.

Consider retatrutide (now or when approved) if:

• You've plateaued on tirzepatide or semaglutide and want more. Some women hit a wall at 15–18% loss. The glucagon receptor activation in retatrutide may push past that ceiling.
• You have significant metabolic factors where the third receptor matters. Diagnosed fatty liver (MASLD/MAFLD), high fasting insulin, or stubborn visceral fat that hasn't budged on a dual agonist. The liver fat reduction data from the Phase 2 trial is remarkable.
• Your goal is 25%+ body weight loss and you're willing to accept a higher side-effect burden to get there.
• You're already peptide-experienced and comfortable working with a peptide-literate provider on research compounds. You know how to manage GI side effects, you've done subcutaneous injections, and you understand you're working with newer data.

The waiting tax is real. If you're 42 and you spend 18 months waiting for retatrutide approval, that's 18 months of carrying weight that affects your joints, your energy, your hormones, and frankly, how you feel when you get dressed in the morning. Starting tirzepatide now and potentially switching to retatrutide later is a completely reasonable strategy. There's no published data on whether prior use of one incretin agonist reduces the effectiveness of a different one. Mechanistically, there's no known reason it would, but this specific question simply hasn't been studied yet. Talk to your provider before planning any switching strategy.

One thing worth planning for now: rapid weight loss on either compound can change your face and skin faster than you expect. If you're losing 20%+ of your body weight, having a skin and face repair plan ready before you need it makes a real difference.

---

Your Route Map: Next Steps Based on Where You Are

If you've never tried a GLP-1 peptide: You don't need to decide between tirzepatide and retatrutide today. You need to figure out which compound fits your body, your goals, and your budget right now. Build your personalized plan based on your weight loss goal, medical history, and timeline.

If you're currently on semaglutide and curious about upgrading: The switch from semaglutide to tirzepatide is well-traveled territory. Bring this to your provider with a specific ask: "I've been on semaglutide for X months, I've lost Y%, and I want to discuss whether tirzepatide's dual-agonist mechanism could get me further." They'll typically want to see your current dose, your weight loss curve (has it flattened?), and your side-effect tolerance before recommending the switch. Most women transition without a washout period.

If you're specifically interested in retatrutide: Track the TRIUMPH trial program. TRIUMPH-4 results were announced in December 2025, and additional trials are reporting through 2026–2027. The head-to-head trial against tirzepatide (NCT06662383) is the one to watch. Set a calendar reminder for Q4 2026 to reassess the approval timeline. In the meantime, a peptide-literate clinic or anti-aging medicine provider is the right conversation partner if you want to explore research compound access.

If you're already on tirzepatide and it's working: Stay on it. Seriously. The best peptide protocol is the one that's producing results and that you'll maintain. You can always add or switch later. Retatrutide isn't going anywhere, and being 6 months into a successful tirzepatide protocol when retatrutide launches means you'll switch from a position of strength, not desperation. If you're also thinking about body recomp after 40, that's a separate conversation worth having with your provider once your weight loss stabilizes.

Whatever your starting point, the quiz maps your situation to a specific route. It takes 2 minutes and it's the fastest way to stop researching and start moving.

---

FAQ

Is retatrutide stronger than tirzepatide for weight loss? Yes, based on current data. Retatrutide 12mg produced 28.7% body weight loss at 68 weeks versus tirzepatide 15mg at 22.5% at 72 weeks. A network meta-analysis confirmed retatrutide's statistical superiority on both absolute and percentage weight reduction. The direct head-to-head trial will give us definitive confirmation, likely by 2027–2028.

When will retatrutide be FDA approved? The earliest realistic timeline is late 2026, with 2027 more likely. Eli Lilly's TRIUMPH Phase 3 program is ongoing, with TRIUMPH-4 results announced in December 2025. The FDA typically requires 12–18 months from submission to approval, and Lilly hasn't filed yet as of mid-2025.

Can I get retatrutide prescribed right now? There is no legal prescription pathway for retatrutide in the United States as of 2025. It has not been FDA-approved for any indication. Some women access it through peptide-focused clinics as a research compound. Important to know: research compounds are not manufactured under FDA oversight, so purity, sterility, and accurate dosing cannot be guaranteed. There are also no legal consumer protections or formal adverse-event monitoring outside a clinical trial. A peptide-literate provider or anti-aging medicine specialist is the right person to discuss testing and monitoring protocols with if you go this route.

Do tirzepatide and retatrutide have the same side effects? The GI side effects (nausea, diarrhea, vomiting) are similar in type and timing for both. Retatrutide has a higher overall adverse-event rate (RR 4.10 vs. 2.78 compared to placebo) and uniquely shows dose-dependent heart rate increases that peak around week 24 and then decline. Both compounds' side effects are concentrated during dose escalation and typically improve with time.

How much weight can a woman realistically lose on tirzepatide? In the SURMOUNT-1 trial, the average loss on the highest dose (15mg) was 22.5% of body weight over 72 weeks. That's about 52 lbs for someone starting at 230 lbs. 57% of participants lost 20% or more. Individual results vary based on starting weight, metabolic health, diet, and activity level, but 15–22% loss over 12–18 months is the realistic range most women report.

Will retatrutide replace tirzepatide once it's approved? Unlikely. They'll probably coexist as options, similar to how semaglutide and tirzepatide coexist now. Tirzepatide has a milder side-effect profile, years of real-world safety data, and will be significantly cheaper (especially compounded) by the time retatrutide launches at premium pricing. Some women will prefer the stronger compound. Others will get everything they need from tirzepatide with fewer side effects. Having both options is a win.

Can I switch from tirzepatide to retatrutide later? There's no clinical data yet on switching protocols, but mechanistically there's no reason you couldn't transition. Both are incretin-based peptides. Your provider would likely taper tirzepatide and start retatrutide at its lowest dose to manage the GI adjustment period. Being experienced with GLP-1 side effects actually makes the transition easier, not harder.

Does retatrutide cause more nausea than tirzepatide? The GI side-effect profiles are broadly similar in the trials, but retatrutide's overall adverse-event rate is higher. The Phase 2 data showed that starting at 2mg instead of 4mg partially mitigated GI issues, which is why slow titration will likely be standard. Women who've tolerated tirzepatide's GI effects typically report that the adjustment period feels familiar.

What does compounded tirzepatide cost per month without insurance? In 2025, compounded tirzepatide through telehealth providers typically runs $250–500/month, depending on your dose and the specific provider. Lower doses (2.5–5mg) are at the lower end; higher doses (10–15mg) push toward the upper end. This compares to $1,000–1,200/month for brand Zepbound or Mounjaro at list price without insurance.

Are the retatrutide weight loss results different for women vs men? The published Phase 2 and Phase 3 data haven't broken out sex-specific results in detail yet. In GLP-1 trials generally, women and men tend to lose similar percentages of body weight, though women sometimes lose slightly less in absolute pounds (because they typically start at lower body weights). The TRIUMPH program's full publications, expected in 2026–2027, should provide sex-stratified data. Women on research protocols anecdotally report results consistent with the trial averages.